tetano
Editor, Senior Moderator
Microbes Infect
. 2021 Mar 17;104811.
doi: 10.1016/j.micinf.2021.104811. Online ahead of print.
COVID-19 Vaccine Decisions: Considering the Choices and Opportunities
Peter J Hotez[SUP] 1 [/SUP], Tasmiah Nuzhath[SUP] 2 [/SUP], Timothy Callaghan[SUP] 3 [/SUP], Brian Colwell[SUP] 2 [/SUP]
Affiliations
Abstract
In the coming months, most American adults will have the opportunity to receive at least one of up to five different COVID-19 vaccines produced by Operation Warp Speed and released through emergency use authorization by the U.S. Food and Drug Administration (FDA). A similar group of vaccines will also be released in Europe by the European Medicines Agency (EMA) and in the United Kingdom by the Medicines & Healthcare products Regulatory Agency (MHRA). Those living outside of North America and Europe may not have access to those particular vaccines, but they will benefit from receiving vaccines produced in Brazil, China, India, or Russia. These vaccines and some of their major features based on clinical trials and testing are listed in Table 1 [1-25]. As vaccine scientists and policy experts working in the area of coronavirus disease 2019 (COVID-19), we are frequently asked about potential choices regarding the available vaccines, both in the U.S. and globally. Provided here is a summary and informal decision-making tool kit for considering the different vaccine options at this time.
. 2021 Mar 17;104811.
doi: 10.1016/j.micinf.2021.104811. Online ahead of print.
COVID-19 Vaccine Decisions: Considering the Choices and Opportunities
Peter J Hotez[SUP] 1 [/SUP], Tasmiah Nuzhath[SUP] 2 [/SUP], Timothy Callaghan[SUP] 3 [/SUP], Brian Colwell[SUP] 2 [/SUP]
Affiliations
- PMID: 33744495
- DOI: 10.1016/j.micinf.2021.104811
Abstract
In the coming months, most American adults will have the opportunity to receive at least one of up to five different COVID-19 vaccines produced by Operation Warp Speed and released through emergency use authorization by the U.S. Food and Drug Administration (FDA). A similar group of vaccines will also be released in Europe by the European Medicines Agency (EMA) and in the United Kingdom by the Medicines & Healthcare products Regulatory Agency (MHRA). Those living outside of North America and Europe may not have access to those particular vaccines, but they will benefit from receiving vaccines produced in Brazil, China, India, or Russia. These vaccines and some of their major features based on clinical trials and testing are listed in Table 1 [1-25]. As vaccine scientists and policy experts working in the area of coronavirus disease 2019 (COVID-19), we are frequently asked about potential choices regarding the available vaccines, both in the U.S. and globally. Provided here is a summary and informal decision-making tool kit for considering the different vaccine options at this time.